Loading…
Based on limited metadata without access to the full warning letter text, Neobiosis, LLC, a biologics manufacturer, received an FDA warning letter on June 5, 2024, though the specific violations are not detailed in the available information. The letter was issued under FDA's biologics regulatory authority, which oversees therapeutic and diagnostic biological products. Without the complete subject line and violation details, the precise nature of the compliance concerns cannot be determined from this metadata alone. A review of the full warning letter would be necessary to identify the specific manufacturing, labeling, or safety deficiencies cited by the agency.